Jakubowski’s efforts at Lilly Research Laboratories (LRL) resulted in several novel molecules undergoing preclinical and clinical evaluation with two, Abciximab (ReoPro) and Prasugrel (Effient), ultimately being approved by the Federal Drug Administration. Jakubowski played key roles in the submission and subsequent commercialization of these two antithrombotic medications. These successes were in part the result of effective external collaborations that he pursued with academia, and biotechnology and large pharma companies, both domestic and international.